Brief timeline and flunding history © 2011 Fluxion Biosciences. All rights reserved. Fluxion today • Company: – Venture backed since Dec 2007 – 4 products commercialized and selling globally – Segment: Biotools – Over 100 units installed • Products: instruments and consumables – BioFlux System for cell-cell interactions – IonFlux Automated Patch Clamp System – IsoFlux rare cell isolation platform – under development BioFlux 200 BioFlux 1000 © 2011 Fluxion Biosciences. All rights reserved. IonFlux-16 IonFlux HT Page 2 Partial customer list Johnson & Johnson © 2011 Fluxion Biosciences. All rights reserved. Page 3 IonFlux applications • Compound profiling – Dose response measurements – Hit confirmation – Single concentration screening • Mutant screening – Evaluate functional changes dependent on mutations – Record responses from up to 32 distinct mutants (8 for IF-HT) • Structure-function studies – – – – Determine the effect of mutations on channel function Characterize expression for differentiated stem cells Recording endogenously expressed ion channels Screen clones based on ion channel density © 2011 Fluxion Biosciences. All rights reserved. Page 4 IonFlux Technology for APC - Best in Class • High quality data – G-seal quality recordings – Ensemble recording for improved success rate • Cost effective – Perform APC for about the cost of an MPC setup • Simple to use – Ease of use of a ‘plate reader’ – Relevance of patch clamp data – Table top unit • Reliable – No robotics required – Only two moving parts © 2011 Fluxion Biosciences. All rights reserved. Page 5 Ensemble vs. single cell recording • Ensembles average signals over 20 patched cells (16 ensembles per plate, left panel) • The new single cell consumable records from one cell per channel (16 cells per plate for IF-16, right panel) • The single cell consumable utilizes the same hardware 20-cell ensemble © 2011 Fluxion Biosciences. All rights reserved. Single cell Page 6 Well-Plate Integrated Microfluidics Well-plate integrated microfluidics (WPM) utilizes standard 96- and 384well plates, but the bottom of the plate is replaced with a microfluidic network interconnected between the wells. © 2010 2011 Fluxion Biosciences. All rights reserved. Page 7 * Sample customer slide – Pfizer UK © 2011 Fluxion Biosciences. All rights reserved. Page 8 High Level Timeline Grant 2 Ph1 Founded Grant 2 Ph2 2006 2007 2008 Grant 1 Ph2 Grant 1 Ph1 2009 2010 2011 IonFlux product launch BioFlux product launch Series A © 2011 Fluxion Biosciences. All rights reserved. Series B Page 9 Grant pipeline and success rates © 2011 Fluxion Biosciences. All rights reserved. Page 10 SBIR: the good, the bad and the ugly • The good: – Non-dilutive capital! – Can be the catalyst for new projects, encourages innovation – Early $$, which are the hardest • The bad: – Long timelines: 9 mo. from application to funding – <200k is low capital for Phase I awards – Can be a distraction from the central mission • The ugly: – Review process dependent on random events – In our case, projects with the greatest commercial worth didn’t get funded © 2011 Fluxion Biosciences. All rights reserved. Page 11